虚拟现实用于颅底肿瘤与颅内血管病变患者知情同意:一项先导研究
该先导研究纳入2023年5月至12月拟行颅底脑膜瘤或脑动脉瘤手术的18至75岁患者,在标准知情同意后使用患者个体化VR模型进行VR增强知情同意,以5点Likert量表问卷评估主观感受。10例患者总体评价积极(均值4.22±0.84),对病理理解(均值4.30±0.92)和拟行手术理解(均值3.95±1.04)较好,信任外科医生均值3.47±0.94,VR相关副作用轻微(均值4.60±0.22),无退出。作者结论为VR增强知情同意可行,可改善患者理解与满意度且无明显副作用,并将指导随机对照试验的规划以进一步验证其获益。
要点
- 10例患者中6例(60%)行动脉瘤夹闭术、4例(40%)行颅底脑膜瘤切除术。
- VR增强知情同意总体评价均值4.22±0.84,病理理解均值4.30±0.92。
- VR相关副作用轻微(均值4.60±0.22),无参与者退出研究。
核心结论
- 作者结论为VR增强知情同意可行,可改善患者理解与满意度且无明显副作用,这些发现将指导随机对照试验的规划以进一步验证VR-IC在神经外科中的获益。
研究设计与样本
- 先导研究,纳入2023年5月至12月拟行颅底脑膜瘤或脑动脉瘤手术、年龄18至75岁的患者。
- 排除标准为视觉/听觉障碍及严重认知/精神疾病。
- 患者在标准知情同意后接受使用其个体化病理VR模型的VR增强知情同意,先由外科医生演示,随后患者独立使用VR设备。
- 采用含18个问题的5点Likert量表问卷评估对VR-IC的主观印象。
主要发现
- 共10例患者参与,其中6例(60%)行动脉瘤夹闭术、4例(40%)行颅底脑膜瘤切除术。
- 参与者平均年龄58岁(±15,范围27至75岁),女性4例(40%)。
- 患者对VR-IC总体评价积极,均值4.22(±0.84)。
- 对自身病理的理解均值4.30(±0.92),对拟行手术的理解均值3.95(±1.04),对外科医生的信任均值3.47(±0.94)。
- VR体验相关副作用轻微,包括头晕或不适,均值4.60(±0.22);无参与者退出研究。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: With the growing demand for shared decision-making and patient-centered care, optimal informed consent (IC) has gained relevance. Virtual reality (VR) has seen significant technological advancements, and its medical applications currently include surgical planning and medical education. This pilot study investigates the feasibility of VR-enhanced informed consent (VR-IC) in neurosurgery to improve preoperative IC and patient satisfaction. METHODS: We included patients aged 18 to 75 years who were scheduled for skull base meningioma or brain aneurysm surgery between May and December 2023. Exclusion criteria were visual/auditory impairments and severe cognitive/psychiatric disorders. Patients received standard IC followed by VR-IC using patient-specific VR models of their pathology. After an initial demonstration by the surgeon, the patients used the VR station independently. A questionnaire with 18 questions on a 5-point Likert scale assessed the subjective impression of VR-IC. RESULTS: Ten patients participated in the study, with six (60%) undergoing aneurysm clipping and four (40%) undergoing skull base meningioma resection. The mean age of the participants was 58 years (± 15, range 27 to 75 years), with four female patients (40%). Patients overall rated the VR-informed consent (VR-IC) positively with a mean of 4.22 (± 0.84). There was a better understanding of their pathology (mean 4.30 ± 0.92) and the planned procedure (mean 3.95 ± 1.04). Trust in the surgeon was rated with a mean of 3.47 (± 0.94). Only minimal side effects from the VR experience including dizziness or discomfort were noted (mean 4.60 ± 0.22). None of the participants dropped out of the study. CONCLUSION: VR-enhanced informed consent is feasible and improves patient understanding and satisfaction without significant side effects. These findings will guide the planning of a randomized controlled trial to validate the benefits of VR-IC in neurosurgery further.
引用
- Westarp E, Saemann A, Zelechovski M, et al. Virtual reality for patient informed consent in skull base tumors and intracranial vascular pathologies: A pilot study. Acta Neurochir (Wien). 2024. PMID: 39546033. doi:10.1007/s00701-024-06355-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。